B
Bull
Bull · 25%ABVC
$3.35
Szenariopreis
$0.830
+0.036 (+4.31%)Zum Schluss
Loading chart…
- High
- 0.850
- Open
- 0.840
- VWAP
- 0.83
- Vol
- 94.14K
- Mkt Cap
- 8.88M
- Low
- 0.810
- Amount
- 78.13K
- EV/EBITDA, TTM
- 0.00
ABVC Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of new drugs and medical devices, all of which are derived from plants. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV-1501, and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine. ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer.
AI analysis of ABVC Biopharma Inc (ABVC)
sellABVC Biopharma Inc is not a good buy right now due to its significant financial losses and declining stock performance. The current price is $0.83, which is down 62.10% year-to-date and 69.60% over the past year. Additionally, the company reported a net income loss of $2,225,022 in Q2 2025, indicating ongoing financial struggles. The main risk is the low current ratio of 0.07, suggesting liquidity issues.
Bewertungskennzahlen
The current forward P/E ratio for ABVC Biopharma Inc (ABVC) is 0.00, compared to its 5-year average forward P/E of -2.39.
Alphio AI Price Scenarios for ABVC
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
8.501-15NASDAQ.COMPlus Therapeutics Prices Public Offering, Raising $15 Million
9.009-23Yahoo FinanceABVC BioPharma, Inc. (ABVC) Sees 103% Increase in Assets, Preparing for Phase III Trials of Depression Treatments
9.508-14NASDAQ.COMAbvc BioPharma Doubles Assets in Q2
9.012-19NewsfilterABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21
- 7.512-11Newsfilter
ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners
ABVC FAQ — answered by Alphio AI
ABVC Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of new drugs and medical devices, all of which are derived from plants. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV-1501, and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine. ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
ABVC Biopharma Inc is not a good buy right now due to its significant financial losses and declining stock performance. The current price is $0.83, which is down 62.10% year-to-date and 69.60% over the past year. Additionally, the company reported a net income loss of $2,225,022 in Q2 2025, indicating ongoing financial struggles. The main risk is the low current ratio of 0.07, suggesting liquidity issues.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.